About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs

By: via Business Wire

Companies to Explore Opportunities to Integrate Biocorp’s Injay® Technology with BD UltraSafePlus™ Passive Needle Guard to Help Biopharmaceutical Manufacturers Capture and Transmit Self-Administered Injection Data.

Regulatory News:

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in France, today announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics.

To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp’s Injay® technology – a solution designed to capture and transmit injection events using Near Field Communication (NFC) technology – to the BD UltraSafe Plus™ Passive Needle Guard used with prefillable syringes.

“Connected drug delivery devices play an important role in helping biopharmaceutical manufacturers understand and track key trends in patient adherence,” said Matthew Schabacker, vice president and general manager of Advanced Drug Delivery Solutions at BD. “Our agreement with Biocorp enables us to explore innovative solutions in this market and further supports BD’s commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes — as we combine Biocorp’s expertise in developing and commercializing connected drug delivery devices to our existing portfolio of advanced injection drug delivery systems.”

Biocorp’s Injay® is a simple and cost-effective connected solution designed to monitor the use of pre-fillable syringes in clinical studies or routine care. Through NFC technology and specific sensors to identify the product, it can confirm a complete injection and easily transfer that information to a smartphone.

“We are very proud to announce this collaboration with BD, a worldwide leader in pre-filled syringes and safety device market,” said Eric Dessertenne, CEO of Biocorp. “It shows the leading position of Biocorp in the field of smart drug delivery devices and addresses an unmet need in the market today.”

The increased prevalence of self-administered therapies for chronic diseases coupled with the pervasiveness of digital technologies in everyone’s life open new opportunities to improve outcomes and experience for patients and to increase the ability to monitor medication adherence.

The global connected drug delivery market is expected to grow at double digit growth rates1 over the next decade – fueled by the transition from acute care settings to home care and the increased prevalence of self-administered therapies. Today, BD is a world leader in supplying prefillable syringes and safety systems to the biopharmaceutical industry – with approximately 70 percent of the top 100 biopharmaceutical companies using BD devices, and more than one billion BD UltraSafe™ units2 sold since 2010 being used to administer over 40 different drugs.3

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

About Biocorp

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 75 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit www.biocorpsys.com.

1 Grandview Research CDDD Market, Data Bridge Market Research Global CDDD Market

2 As of 2020

3 Drug products approved with BD UltraSafe™ solutions. Includes both BD UltraSafe Passive™ and BD UltraSafe Plus™ passive needle guards

Contacts

More News

View More
Lower Rates Put RV Stocks Back in the Fast Lane
Via MarketBeat
Tickers CWH THO WGO
Alphabet: Time to Take Profits, Buy, or Wait for a Pullback?
Via MarketBeat
Topics Artificial Intelligence
Tickers GOOGL
Hershey vs. Mondelez: Which Stock Wins Chocolate Season?
Via MarketBeat
Topics Economy
Tickers HSY MDLZ PEP
Thor Industries Tracking for New Highs in 2026
Via MarketBeat
Topics Economy
Tickers THO
Cintas Stock Sends a Clear Buy Signal as Momentum Builds
Via MarketBeat
Topics Government
Tickers CTAS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.